Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|September 2, 2020
- Pharmaceutical Technology-09-02-2020
- Volume 44
- Issue 9
Ultra-High Shear Mixer
Author(s)Pharmaceutical Technology Editors
MegaShear from Ross is a patented ultra-high shear rotor/stator mixer for high-throughput emulsification, dispersion, and homogenization.
MegaShear from Ross is a patented ultra-high shear rotor/stator mixer for high-throughput emulsification, dispersion, and homogenization. The device features 11,300 ft/min tip speed and can reach a level of shear typically only seen in high-pressure homogenizers.
The MegaShear Model HSM-706M-50 (pictured) comes equipped with a 50HP motor for creating high-quality dispersions, suspensions, and emulsions for the food, cosmetic, pharmaceutical and nutraceutical, chemical, coatings, electronics, and composites industries. The MegaShear is also less sensitive to clogging and changes in viscosity compared to other high-pressure homogenizers.
Articles in this issue
about 5 years ago
Moving Forward in Serializationabout 6 years ago
Preparing Pandemic Vaccine Capacityabout 6 years ago
Tracking API Quality During a Pandemicabout 6 years ago
Capsule Innovations: Speeding Up Drug Developmentabout 6 years ago
Manufacturing Drug–Device Combination Productsabout 6 years ago
Advancing Understanding of a Traditional Techniqueabout 6 years ago
Pharmacovigilance Under Scrutiny: Why Companies are Falling Shortabout 6 years ago
Pharmacopoeia Compliance: A Practical Guideabout 6 years ago
Streamlining Method Transfer Across Global SitesRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5